Clinical Trials Logo

Major Depressive Disorder clinical trials

View clinical trials related to Major Depressive Disorder.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06372210 Completed - Schizophrenia Clinical Trials

A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion

Start date: June 26, 2023
Phase: N/A
Study type: Interventional

The primary purpose of the study is to evaluate the positive detection accuracy (PDA) and detection latency measures of the D-Tect patch.

NCT ID: NCT06331572 Completed - Clinical trials for Major Depressive Disorder

Exploring Blood Plasma Metabolomics: Unraveling the Metabolic Landscape in Treatment-Resistant Adolescent Depression

Start date: August 1, 2021
Phase:
Study type: Observational

This study contributes new evidence for the identification of adolescent TRD and sheds light on differing pathophysiologies by delineating distinct plasma metabolic profiles between adolescent TRD and FEDN-MDD.

NCT ID: NCT06114342 Completed - Clinical trials for Major Depressive Disorder

The Biological Specificity of Acupoints Between Major Depressive Disorder Patients and Healthy Controls

Start date: January 10, 2022
Phase:
Study type: Observational

Evidence-based medicine suggests that acupuncture can improve major depressive disorder (MDD). However, the prevalent reliance on experiential acupoint selection lacks scientific underpinning. The investigators conducted a comparative study involving MDD patients and healthy subjects, employing modern techniques to discern biological specificity in MDD-related acupoints. Additionally, the investigators investigated potential correlations between acupoint biological specificity and MDD severity.

NCT ID: NCT06113575 Completed - Clinical trials for Major Depressive Disorder

Practical Application of Accelerated iTBS for MDD

Start date: November 23, 2022
Phase: N/A
Study type: Interventional

The goal of this observational study is to evaluate the feasibility and efficacy of accelerated iTBS in adults diagnosed with Major Depressive Disorder. The main question it aims to answer is: What is the efficacy and tolerability of an accelerated iTBS regimen without radiological imaging in adults who have been diagnosed with Major Depressive Disorder and experience treatment resistant symptoms? Participants will complete 36 iTBS treatments in an accelerated schedule over five days. They will also complete several clinical assessments throughout their enrollment to evaluate their depressive symptoms and response to treatment.

NCT ID: NCT06003361 Completed - Clinical trials for Major Depressive Disorder

Rise Study for Depression

Start date: August 31, 2023
Phase: N/A
Study type: Interventional

This study will examine the efficacy of digital CBT versus waitlist in improving symptoms for adults with Major Depressive Disorder.

NCT ID: NCT05952713 Completed - Clinical trials for Major Depressive Disorder

Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder

Start date: October 1, 2022
Phase:
Study type: Observational

Achieving results from RCTs with high internal and external validity is a major challenge within psychiatry due to the nature of psychiatric illnesses. The Investigators will conduct a "real world" naturalistic nation-wide population-based longitudinal register linkage study comparing long-term responses to all kinds of antidepressants in patients with major depressive disorder emulating a randomized trial.

NCT ID: NCT05950061 Completed - Clinical trials for Major Depressive Disorder

Sertraline Versus Escitalopram in South Asian Participants With Moderate to Severe Major Depressive Disorder

Start date: June 1, 2022
Phase: Phase 3
Study type: Interventional

Objective: The aim of this randomized controlled trial was to compare the efficacy and safety of sertraline and escitalopram in participants with moderate to severe major depressive disorder (MDD). Methods: A total of 744 participants with moderate to severe MDD were randomly assigned to receive either sertraline or escitalopram for 8 weeks. Drug dosages and titration schedules were based on the recommendations of the prescribing information for each product and according to the judgment of the clinicians involved in the study. The primary outcome measures were changes from baseline on the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Clinical Global Impression (CGI) scale as well as frequency of adverse events in both groups.

NCT ID: NCT05905120 Completed - Clinical trials for Major Depressive Disorder

Assessing Dopamine Transporter Occupancy in the Healthy Adult Brain With Toludivenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)

Start date: March 2, 2023
Phase: Phase 1
Study type: Interventional

This study was a single-arm, non-randomized, open-label clinical study to assess dopamine transporter occupancy in the brain of healthy adults using 11C-CFT positron emission tomography (PET)

NCT ID: NCT05866042 Completed - Clinical trials for Major Depressive Disorder

Boosting Psychotherapy Effects by Means of Transcranial Direct Current Stimulation

PSYCHOBOOST
Start date: May 1, 2021
Phase: N/A
Study type: Interventional

The present study involves the administration of three types of interventions in patients with depressive episode in the context of DDM. Two-thirds of the patients will carry out a course of excitatory tDCS sessions on the left DLPFC, so as to improve attention regulation on information characterized by negative emotions and have an antidepressant effect, simultaneously with the performance of a task, the attentional training technique (ATT), aimed at achieve effective management of emotions characterized by negative emotions and which constitutes a fundamental exercise of MCT. In half of the patients who will undergo tDCS treatment, after each session of stimulation, an MCT session will be carried out. In addition, before and after the cycle of tDCS sessions and MCT sessions will be explored, in a subgroup of patients, in the context of a pilot study, the TMS- EEG of the change in depressive symptomatology, which can be correlated with the different proposed therapeutic interventions.

NCT ID: NCT05815459 Completed - Clinical trials for Major Depressive Disorder

Mobile Observation Of Depression

MOOD
Start date: July 15, 2022
Phase:
Study type: Observational

The primary aim of this project is to test if OCOsense glasses can function as a digital phenotyping tool derived from behavioural and physiological signals related to facial expression and motion recorded using the glasses.